<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507468</url>
  </required_header>
  <id_info>
    <org_study_id>ABM-MI-10</org_study_id>
    <nct_id>NCT00507468</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone</brief_title>
  <acronym>TABMMI</acronym>
  <official_title>Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCardia, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The object of this open-labeled, uncontrolled pilot study was to investigate the safety and
      feasibility of percutaneously transplanting autologous bone marrow (ABM) cells into the
      myocardium using the helical needle transendocardial (TE) delivery system in stable coronary
      patients with ventricular dysfunction due to chronic myocardial infarction (MI).

      A secondary goal was to assess the possibility that such cell injections could improve
      ejection fraction (EF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of treatment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Ventricular Dysfunction</condition>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transendocaridal Transplantation of Autologous Bone Marrow</intervention_name>
    <description>Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18 years of age or older

          -  Able to give informed consent

          -  Must have documentation of prior myocardial infarction with left ventricular ejection
             fraction of less than 40 percent at baseline

          -  Must be a candidate for percutaneous heart catheterization

          -  Must have identifiable area of transmural scar within the left ventricle

        Exclusion Criteria:

          -  Be a candidate for concurrent ventricular surgical restoration, AICD placement or
             valvular surgery

          -  Clinical evidence of infection

          -  Other complicating cardiovascular abnormalities

          -  Clinically significant electrocardiographic abnormalities

          -  Active malignancy

          -  Recent history or drug or alcohol abuse

          -  Pregnancy, planned or current

          -  Artificial aortic valve

          -  Ejection fraction less than 30 percent at baseline

          -  Myocardial infarction in the past 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis de la Fuente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Argentine Institute of Diagnosis and Treatment</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swiss Clinic</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1118</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Argentine Institute of Diagnosis and Treatment</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1122</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2007</study_first_submitted>
  <study_first_submitted_qc>July 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2007</study_first_posted>
  <last_update_submitted>November 2, 2009</last_update_submitted>
  <last_update_submitted_qc>November 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Peter Altman</name_title>
    <organization>BioCardia, Inc</organization>
  </responsible_party>
  <keyword>bone marrow</keyword>
  <keyword>autologous</keyword>
  <keyword>ejection fraction</keyword>
  <keyword>left ventricle</keyword>
  <keyword>heart attack</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>left ventricular dysfunction post myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

